

"The Pink Sheet"

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, click [here](#) or call +1 (908) 748-1221.

Printed by **Ms. Anne Stemlar, Goodwin Procter**

MTP inhibitor research discontinued

By The Pink Sheet / [Email the Author](#) / [View Full Issue](#)

Briefs / Word Count: **45** / Article # **00620310036** / Posted: **July 31 2000 5:00 AM**

Executive Summary

Development of microsomal transport protein lipid-lowering agent BMS-201038 has been discontinued after Phase II trials showed "adverse events in terms of liver function," Bristol Chief Scientific Officer Peter Ringrose, PhD, said. "We've concluded that this is really a mechanism-related effect rather than a molecule-related effect"

Development of microsomal transport protein lipid-lowering agent BMS-201038 has been discontinued after Phase II trials showed "adverse events in terms of liver function," Bristol Chief Scientific Officer Peter Ringrose, PhD, said. "We've concluded that this is really a mechanism-related effect rather than a molecule-related effect".

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, click [here](#) or call +1 (908) 748-1221.

Printed by **Ms. Anne Stemlar, Goodwin Procter**

Copyright (c) 2015 Informa Business Information, Inc., an Informa Company. All rights reserved. No part of this article may be reproduced in any form or incorporated into any information retrieval system without the written permission of the copyright owner.
Online/print subscriptions, reprints, and web posting and distribution licenses are available.
Contact us at (888) 670-8900, +1 (908) 748-1221, or custcare@informa.com.

Related Articles

There are no current related articles

Topics Covered in this Article

[Click a keyword for related articles.](#)